The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesThis antibody inhibits of the biological activity of human native and recombinant IL-6 (determined with the B9 cell bioassay).
1 ml of the antibody solution inhibits approximately 0.33µg of IL-6 per ml.
Before use in biological assays, this antibody must be filter-sterilized and depending on the concentration to be used dialyzed against culture medium to remove sodium azide.
Dilutions have to be made according to the amount of IL-6 to be inactivated.
For Western blots the material should not be diluted.
FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Sequence similaritiesBelongs to the IL-6 superfamily.
Post-translational modificationsN- and O-glycosylated.